구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 4개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||||
|---|---|---|---|---|
Overview Program | Repatha (evolocumab) | Praluent (alirocumab) | Leqvio (inclisiran) | Simvastatin |
Overview Company | Amgen | Sanofi / Regeneron | Novartis | Organon and Co |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | PCSK9 | PCSK9 | PCSK9 (siRNA) | Lymphoma |
Overview Indication | Hyperlipidemia, ASCVD risk reduction, HeFH, HoFH | Hyperlipidemia, ASCVD, HeFH | Hyperlipidemia, ASCVD, HeFH (LDL-C lowering) | Lymphoma |
Overview Phase | APPROVED | APPROVED | APPROVED | PHASE_1 |
Overview Status | APPROVED | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Watch |
Overview Approval status | FDA approved | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | High LDL-C lowering without statin myalgia; autoinjector pen | Flexible q2w dosing; post-ACS outcomes label | Infrequent dosing (q6 months maintenance) | — |
Positioning Known limitation | Statin non-adherence; rare anti-drug antibodies | resistance to immune checkpoint blockade | Injection-site reactions; long-term siRNA durability generally maintained. | — |
Positioning Development positioning | PCSK9 mAb vs inclisiran siRNA (Leqvio) dosing convenience trade-off | — | — | — |
MoA Mechanism | Evolocumab binds PCSK9, preventing PCSK9-mediated LDL receptor degradation on hepatocytes, increasing LDLR recycling and hepatic LDL-C clearance. | Alirocumab inhibits PCSK9, increasing available LDL receptors and lowering LDL-C similarly to evolocumab. | Inclisiran is a GalNAc-conjugated siRNA that catalytically degrades PCSK9 mRNA in hepatocytes, reducing PCSK9 protein and increasing LDLR density. | blocks bacterial invasion by targeting key host factors, including collagen I (using FT011), lipid rafts (using simvastatin), integrin β1 (using ATN-161), and FAK signaling |
MoA Biomarker | LDL-C, ApoB, non-HDL-C; Lp(a) modest reduction. | LDL-C, ApoB. | LDL-C, PCSK9 protein levels. | biomarkers |
PK/PD Half-life | 17 h | 12 h | 9 h | — |
PK/PD Species | Mouse | Mouse, LDL-C ↓~58% | Mouse, Rat | Rat |
PK/PD Animal (cat.) | Mouse, In vitro | Mouse | Mouse, Rat, Monkey | Rat, In vitro |
PK/PD Experiment | pharmacokinetic | pharmacokinetic | pharmacokinetic | PD |
Toxicology Species | Cynomolgus monkey, Mouse, Hamster | Mouse, Rat | Mouse, Rat | Rat |
Toxicology Animal (cat.) | NHP | — | — | Rat, In vitro |
Toxicology Major finding | No major organ toxicity; injection-site reactions | Injection-site reactions, flu-like symptoms. | Injection-site reactions, arthralgia, urinary tract infection. | Effects of Hedan Tablets Combined With Simvastatin on Hyperlipidemia: Insights From Microbiomics and Metabolomics.. Simvastatin (ST) has limited long-term clinical utility due to its adverse effects. The combination of Hedan tablets and simvastatin (HST) exhibits superior lipid-lowering effects, but its mechanism remains unclear. This study aims to investigate the effects of HST in hyperlipidemic … |
Toxicology CRS | N/A | N/A | N/A | — |
Clinical Safety signal | No major organ toxicity; injection-site reactions | Injection-site reactions, flu-like symptoms. | Injection-site reactions, arthralgia, urinary tract infection. | Effects of Hedan Tablets Combined With Simvastatin on Hyperlipidemia: Insights From Microbiomics and Metabolomics.. Simvastatin (ST) has limited long-term clinical utility due to its adverse effects. The combination of Hedan tablets and simvastatin (HST) exhibits superior lipid-lowering effects, but its mechanism remains unclear. This study aims to investigate the effects of HST in hyperlipidemic … |
Clinical Selected reported efficacy | 67% | — | — | — |
Clinical Result source | ClinicalTrials.gov NCT05144529 | — | — | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED | PHASE_1 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | — |
Clinical Trial ref | NCT05144529 | — | — | — |
Preclinical Animal (cat.) | Mouse, In vitro | Mouse | Mouse | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 4개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||||
|---|---|---|---|---|
Overview Program | Repatha (evolocumab) | Praluent (alirocumab) | Leqvio (inclisiran) | Simvastatin |
Overview Company | Amgen | Sanofi / Regeneron | Novartis | Organon and Co |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | PCSK9 | PCSK9 | PCSK9 (siRNA) | Lymphoma |
Overview Indication | Hyperlipidemia, ASCVD risk reduction, HeFH, HoFH | Hyperlipidemia, ASCVD, HeFH | Hyperlipidemia, ASCVD, HeFH (LDL-C lowering) | Lymphoma |
Overview Phase | APPROVED | APPROVED | APPROVED | PHASE_1 |
Overview Status | APPROVED | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Watch |
Overview Approval status | FDA approved | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | High LDL-C lowering without statin myalgia; autoinjector pen | Flexible q2w dosing; post-ACS outcomes label | Infrequent dosing (q6 months maintenance) | — |
Positioning Known limitation | Statin non-adherence; rare anti-drug antibodies | resistance to immune checkpoint blockade | Injection-site reactions; long-term siRNA durability generally maintained. | — |
Positioning Development positioning | PCSK9 mAb vs inclisiran siRNA (Leqvio) dosing convenience trade-off | — | — | — |
MoA Mechanism | Evolocumab binds PCSK9, preventing PCSK9-mediated LDL receptor degradation on hepatocytes, increasing LDLR recycling and hepatic LDL-C clearance. | Alirocumab inhibits PCSK9, increasing available LDL receptors and lowering LDL-C similarly to evolocumab. | Inclisiran is a GalNAc-conjugated siRNA that catalytically degrades PCSK9 mRNA in hepatocytes, reducing PCSK9 protein and increasing LDLR density. | blocks bacterial invasion by targeting key host factors, including collagen I (using FT011), lipid rafts (using simvastatin), integrin β1 (using ATN-161), and FAK signaling |
MoA Biomarker | LDL-C, ApoB, non-HDL-C; Lp(a) modest reduction. | LDL-C, ApoB. | LDL-C, PCSK9 protein levels. | biomarkers |
PK/PD Half-life | 17 h | 12 h | 9 h | — |
PK/PD Species | Mouse | Mouse, LDL-C ↓~58% | Mouse, Rat | Rat |
PK/PD Animal (cat.) | Mouse, In vitro | Mouse | Mouse, Rat, Monkey | Rat, In vitro |
PK/PD Experiment | pharmacokinetic | pharmacokinetic | pharmacokinetic | PD |
Toxicology Species | Cynomolgus monkey, Mouse, Hamster | Mouse, Rat | Mouse, Rat | Rat |
Toxicology Animal (cat.) | NHP | — | — | Rat, In vitro |
Toxicology Major finding | No major organ toxicity; injection-site reactions | Injection-site reactions, flu-like symptoms. | Injection-site reactions, arthralgia, urinary tract infection. | Effects of Hedan Tablets Combined With Simvastatin on Hyperlipidemia: Insights From Microbiomics and Metabolomics.. Simvastatin (ST) has limited long-term clinical utility due to its adverse effects. The combination of Hedan tablets and simvastatin (HST) exhibits superior lipid-lowering effects, but its mechanism remains unclear. This study aims to investigate the effects of HST in hyperlipidemic … |
Toxicology CRS | N/A | N/A | N/A | — |
Clinical Safety signal | No major organ toxicity; injection-site reactions | Injection-site reactions, flu-like symptoms. | Injection-site reactions, arthralgia, urinary tract infection. | Effects of Hedan Tablets Combined With Simvastatin on Hyperlipidemia: Insights From Microbiomics and Metabolomics.. Simvastatin (ST) has limited long-term clinical utility due to its adverse effects. The combination of Hedan tablets and simvastatin (HST) exhibits superior lipid-lowering effects, but its mechanism remains unclear. This study aims to investigate the effects of HST in hyperlipidemic … |
Clinical Selected reported efficacy | 67% | — | — | — |
Clinical Result source | ClinicalTrials.gov NCT05144529 | — | — | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED | PHASE_1 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | — |
Clinical Trial ref | NCT05144529 | — | — | — |
Preclinical Animal (cat.) | Mouse, In vitro | Mouse | Mouse | — |
추천 비교
추천 비교